The UK-based Summit is likely to report results from the initial 24-week dosing period in the first quarter of 2018 which are anticipated to contain data from muscle biopsies,
Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medication that can
Trastuzumab, which is a monoclonal antibody, is the active substance in Ontruzant. This antibody binds with high affinity and specificity to the human epidermal growth factor receptor 2
Hemlibra is a bispecific factor IXa- and factor X-directed antibody. The therapy which has been approved for both adults and children, functions by bridging other factors in the blood
MPS VII is a progressive and debilitating inherited, rare genetic disease which previously didn’t have any approved therapy. It is a metabolic lysosomal storage disorder (LSD) resulting from
Fasenra has been approved as an add-on maintenance treatment for patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. The approval was based
The American company had announced its plan to sell the business in July as it was anticipating that the upcoming drug distribution reform in China will affect its
Sawai America is the parent company of US generics drugmaker Upsher-Smith Laboratories (USL). The deal allows Sawai and Sumitomo to form a strategic alliance in the generic pharmaceuticals
The sensor in Abilify MyCite is ingestible and can also record when the patients had taken the pill. Abilify MyCite has been approved for treating schizophrenia, acute treatment
ABP 215, which is a biosimilar to Avastin (bevacizumab), has been recommended for marketing authorization to treat certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.